The decrease in healthcare-associated methicillin-resistant Staphylococcus aureus infections and savings from glycopeptide use.
We evaluated changes in the rate of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infections and healthcare-associated S. aureus infections after implementation of infection control precautions and the effect of this on glycopeptide use and expenditures for glycopeptides in a private medical center in Turkey in the years 2000-2005. A striking decrease was obtained in the number of MRSA infections, and the expenditure for glycopeptide use also decreased.
Coskun
Diler
D
Department of Microbiology, Medical Faculty, Istanbul Science University, Istanbul, Turkey. dilercoskun@yahoo.com
Aytac
Jale
J
D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology*; D006020:Glycopeptides / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology*; D014421:Turkey / Q000453:epidemiology
D006020:Glycopeptides